Abstract
In the US, approximately two-thirds of adults are classified as overweight or obese, conditions linked to increased risks of hypertension, type 2 diabetes, and cardiovascular disease (CVD).1 The SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial showed that a weight loss dose of semaglutide significantly reduces the incidence of major adverse CVD outcomes in nondiabetic individuals who are either overweight or obese.2 Building on research highlighting variations in the cardiometabolic disease burden across states,3 this study examines the potential impact of the SELECT trial nationally and by state.